Advertisement Third Wave and DCL enter into strategic partnership - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Third Wave and DCL enter into strategic partnership

Third Wave Technologies and DCL Medical Laboratories have forged a strategic partnership under which DCL will serve as a product development, demonstration and marketing partner with Third Wave.

DCL will adopt products from Third Wave’s expanding molecular diagnostic menu and have early access to new assays and equipment developed by Third Wave. Third Wave will establish a research and development laboratory at DCL for joint product research, which will include a customer demonstration facility for Third Wave products.

Michael Hanbury, president and CEO of DCL, said: “Partnering with Third Wave extends DCL’s capabilities as an interventional anatomic pathology team with experienced development and clinical trial services that target the pharmaceutical and medical device industries.”